EA200200331A1 - Применение лептина для ингибирования пролиферации эндотелиальных клеток - Google Patents

Применение лептина для ингибирования пролиферации эндотелиальных клеток

Info

Publication number
EA200200331A1
EA200200331A1 EA200200331A EA200200331A EA200200331A1 EA 200200331 A1 EA200200331 A1 EA 200200331A1 EA 200200331 A EA200200331 A EA 200200331A EA 200200331 A EA200200331 A EA 200200331A EA 200200331 A1 EA200200331 A1 EA 200200331A1
Authority
EA
Eurasian Patent Office
Prior art keywords
leptin
proliferation
inhibit
endothelial cells
published
Prior art date
Application number
EA200200331A
Other languages
English (en)
Other versions
EA005066B1 (ru
Inventor
Менахем Рубинштейн
Батиа Кохен
Далит Баркан
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13173999A external-priority patent/IL131739A0/xx
Application filed by Йеда Рисерч Энд Дивелопмент Ко. Лтд. filed Critical Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Publication of EA200200331A1 publication Critical patent/EA200200331A1/ru
Publication of EA005066B1 publication Critical patent/EA005066B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрывается применение лептина, необязательно вместе с ингибиторами ФРЭС, для ингибирования пролиферации эндотелиальных клеток и модуляции ангиогенеза.Отчет о международном поиске был опубликован 2001.06.14.
EA200200331A 1999-09-05 2000-09-04 Применение лептина для ингибирования пролиферации эндотелиальных клеток EA005066B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13173999A IL131739A0 (en) 1999-09-05 1999-09-05 Use of leptin in inhibition of endothelial cell proliferation
IL13231299A IL132312A0 (en) 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation
PCT/IL2000/000525 WO2001018040A2 (en) 1999-09-05 2000-09-04 Use of leptin in inhibition of endothelial cell proliferation

Publications (2)

Publication Number Publication Date
EA200200331A1 true EA200200331A1 (ru) 2002-08-29
EA005066B1 EA005066B1 (ru) 2004-10-28

Family

ID=26323878

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200331A EA005066B1 (ru) 1999-09-05 2000-09-04 Применение лептина для ингибирования пролиферации эндотелиальных клеток

Country Status (19)

Country Link
EP (1) EP1210108B1 (ru)
JP (1) JP2003508544A (ru)
KR (1) KR100683362B1 (ru)
CN (1) CN1189479C (ru)
AR (1) AR025494A1 (ru)
AT (1) ATE449609T1 (ru)
AU (1) AU781390B2 (ru)
BR (1) BR0013778A (ru)
CA (1) CA2382941C (ru)
DE (1) DE60043391D1 (ru)
EA (1) EA005066B1 (ru)
EE (1) EE05262B1 (ru)
ES (1) ES2335569T3 (ru)
HK (1) HK1048075B (ru)
IL (1) IL132312A0 (ru)
MX (1) MXPA02002448A (ru)
NO (1) NO325989B1 (ru)
UA (1) UA74163C2 (ru)
WO (1) WO2001018040A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355237B1 (en) * 1994-09-14 2002-03-12 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US8633250B2 (en) * 2006-01-12 2014-01-21 Musc Foundation For Research Development Cell repair and regeneration by suramin and related polysulfonated napthylureas
ES2474765T3 (es) 2009-06-17 2014-07-09 National University Corporation Kumamoto University Agente profiláctico y/o terapéutico para la dismenorrea

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0892849T3 (da) * 1996-01-23 2006-07-24 Indevus Pharmaceuticals Inc Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
WO1999059614A1 (en) * 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing

Also Published As

Publication number Publication date
AU781390B2 (en) 2005-05-19
EE200200116A (et) 2003-04-15
CN1189479C (zh) 2005-02-16
EP1210108B1 (en) 2009-11-25
CN1377277A (zh) 2002-10-30
IL132312A0 (en) 2001-03-19
EA005066B1 (ru) 2004-10-28
UA74163C2 (ru) 2005-11-15
BR0013778A (pt) 2002-05-14
ES2335569T3 (es) 2010-03-30
KR100683362B1 (ko) 2007-02-15
NO325989B1 (no) 2008-09-01
NO20020920L (no) 2002-05-03
MXPA02002448A (es) 2002-07-30
HK1048075A1 (en) 2003-03-21
ATE449609T1 (de) 2009-12-15
JP2003508544A (ja) 2003-03-04
DE60043391D1 (de) 2010-01-07
CA2382941A1 (en) 2001-03-15
AU6862000A (en) 2001-04-10
KR20020040781A (ko) 2002-05-30
AR025494A1 (es) 2002-11-27
WO2001018040A3 (en) 2001-06-14
EP1210108A2 (en) 2002-06-05
HK1048075B (zh) 2005-07-29
WO2001018040A2 (en) 2001-03-15
CA2382941C (en) 2011-08-16
NO20020920D0 (no) 2002-02-25
EE05262B1 (et) 2010-02-15

Similar Documents

Publication Publication Date Title
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA200300073A1 (ru) Фармацевтические композиции ингибиторов белка переноса холестериловых эфиров
EA199800633A1 (ru) Новые замещенные производные имидазола
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
FI20000061A (fi) Substituoituja alkanohydroksaamihappoja ja menetelmä TNFalfa-tasojen alentamiseksi
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
EA199900325A1 (ru) Форма d дигидрата оланзапина
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA199900981A1 (ru) Лептин как ингибитор пролиферации опухолевых клеток
EA200201252A1 (ru) Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4
BR9711586A (pt) Compostos e uso dos mesmo
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
DK0954521T3 (da) 4-[(thien-3-yl)methyl]-imidazoler med alfa2-adrenoceptor-agonistisk aktivitet
PT1242410E (pt) Compostos novos
EA200100854A1 (ru) Кальций-литические соединения
EA200200331A1 (ru) Применение лептина для ингибирования пролиферации эндотелиальных клеток
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
ES2179864T3 (es) 4-benzoil-isoxazoles y su uso como herbicidas.
EA200001050A1 (ru) Малеат пароксетина
EA200200189A1 (ru) Применение ингибиторов интерлейкина 18
EA200200798A1 (ru) Кальцилитические соединения
ATE201869T1 (de) 4-((thien-2-yl)methyl)imidazolderivate mit alpha2-adrenoceptor agonistischer aktivität
EA199900241A1 (ru) ЗАМЕЩЕННЫЕ 1,2,3,4-ТЕТРАГИДРО-2-ДИБЕНЗОФУРАНАМИНЫ И 2-АМИНОЦИКЛОГЕПТА [b] БЕНЗОФУРАНЫ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU